• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

VIDEO: CVD Risk Reduction in Primary Care: Diabetes

Video

Jorge Plutzky, MD, director of the Preventive Cardiology Program at Brigham and Women's Hospital, discusses the insidious role diabetes plays in cardiovascular disease.

Dr Jorge Plutzky, director of the Vascular Disease Prevention and Preventive Cardiology Programs at the Brigham and Women’s Hospital talks about the extensive impact of diabetes on the cardiovascular system and its insidious role in cardiovascular disease, from stroke to peripheral neuropathy.

Plutzky emphasizes the essential role for all primary care clinicians in recognizing the risk factors for and earliest signs and symptoms of hyperglycemia and its broad metabolic impact and commends their front-line care.

______________________________________________

Jorge Plutzky, MD, is director, preventive cardiology, at Brigham and Women’s Hospital and on the faculty of Harvard Medical School. Dr Plutzky is a recognized authority on preventive cardiology, bridging basic science and clinical issues that link heart disease to obesity and diabetes. He directs the BWH Lipid/Prevention Clinic along with his NIH-funded basic science laboratory. He is currently chair of the American Heart Association’s Diabetes Committee.

Recent Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
© 2024 MJH Life Sciences

All rights reserved.